Literature DB >> 34059079

Measurement properties of the 12-item Short Form Health Survey version 2 in Australians with lung cancer: a Rasch analysis.

Sze-Ee Soh1,2, Renata Morello3, Darshini Ayton3, Susannah Ahern3, Ri Scarborough3, Claire Zammit3, Margaret Brand3, Robert G Stirling4,5, John Zalcberg3.   

Abstract

BACKGROUND: The 12-item Short-Form Health Survey version 2 (SF-12v2), a widely used, generic patient-reported measure of health status that provides summary scores of physical and mental health. No study to date has examined the measurement properties of the SF-12v2 in patients with lung cancer using Rasch analysis. The aim of this study was to extend the psychometric evaluations of the SF-12 within the lung cancer population to ensure its validity and reliability to assess the health status in this population.
METHODS: Participants in the Victorian Lung Cancer Registry (VLCR) who completed the SF-12v2 between 2012 and 2016 were included in this study. The structural validity of the SF-12v2 was assessed using Rasch analysis. Overall fit to the Rasch measurement model was examined as well as five key measurement properties: uni-dimensionality, response thresholds, internal consistency, measurement invariance and targeting.
RESULTS: A total of 342 participants completed the SF-12v2 three months following their lung cancer diagnosis. The SF-12 Physical Component Score (PCS-12) did not fit the overall Rasch measurement model (χ2 107.0; p < 0.001). Three items deviated significantly from the Rasch model (item fit residual beyond ± 2.5) with signs of dependency between item responses and disordered thresholds. Nevertheless, the PCS-12 was uni-dimensional with good internal consistency (person separation index [PSI] 0.83) and reasonable targeting. In contrast, the SF-12 Mental Component Score (MCS-12) had good overall model fit (χ2 35.1; p = 0.07), reasonable targeting and good internal consistency (PSI 0.81).
CONCLUSIONS: Rasch analysis suggests that there is general support for the reliability of the SF-12v2 as a measure of physical and mental health in people with lung cancer. However, the appropriateness of some items (e.g. pain) in the PCS-12 is questionable and further refinement of the scale including changing the response options may be required to improve the ability of the SF-12v2 to more appropriately assess the health status of this population.

Entities:  

Keywords:  Health status; Lung cancer; Psychometrics; Rasch analysis

Year:  2021        PMID: 34059079     DOI: 10.1186/s12955-021-01794-w

Source DB:  PubMed          Journal:  Health Qual Life Outcomes        ISSN: 1477-7525            Impact factor:   3.186


  1 in total

1.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

  1 in total
  2 in total

1.  Finding My Way from clinical trial to open access dissemination: comparison of uptake, adherence, and psychosocial outcomes of an online program for cancer-related distress.

Authors:  Lisa Beatty; Emma Kemp; Bogda Koczwara
Journal:  Support Care Cancer       Date:  2022-06-22       Impact factor: 3.359

2.  One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals.

Authors:  Mayssam Nehme; Olivia Braillard; François Chappuis; Delphine S Courvoisier; Laurent Kaiser; Paola M Soccal; Jean-Luc Reny; Frederic Assal; Guido Bondolfi; Aglaé Tardin; Christophe Graf; Dina Zekry; Silvia Stringhini; Hervé Spechbach; Frederique Jacquerioz; Julien Salamun; Frederic Lador; Matteo Coen; Thomas Agoritsas; Lamyae Benzakour; Riccardo Favale; Stéphane Genevay; Kim Lauper; Philippe Meyer; Nana K Poku; Basile N Landis; Stéphanie Baggio; Marwène Grira; José Sandoval; Julien Ehrsam; Simon Regard; Camille Genecand; Garance Kopp; Ivan Guerreiro; Gilles Allali; Pauline Vetter; Idris Guessous
Journal:  J Intern Med       Date:  2022-03-31       Impact factor: 13.068

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.